PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16509761-1	2006	BACKGROUND: Ruboxistaurin, a specific inhibitor of the beta(1) and beta(2) isoforms of protein kinase C, is currently in clinical development for the treatment of several diabetic microvascular complications.	ruboxistaurin	12-25	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	67-74	
10470381-1	1999	The macrocyclic bisindolylmaleimide, LY333531, selectively inhibits protein kinase C beta 1 and beta 2 isoforms with an approximate IC50 of 5 nanomolar.	ruboxistaurin	37-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-102